0001104659-22-111246.txt : 20221025
0001104659-22-111246.hdr.sgml : 20221025
20221025173417
ACCESSION NUMBER: 0001104659-22-111246
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221021
FILED AS OF DATE: 20221025
DATE AS OF CHANGE: 20221025
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Daniels Eric Joseph
CENTRAL INDEX KEY: 0001892943
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36672
FILM NUMBER: 221330534
MAIL ADDRESS:
STREET 1: C/O EYEGATE PHARMACEUTICALS INC.
STREET 2: 271 WAVERLY OAKS RD., STE 108
CITY: WALTHAM
STATE: MA
ZIP: 02452
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KIORA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001372514
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1371 EAST 2100 SOUTH
STREET 2: SUITE 200
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84105
BUSINESS PHONE: (781) 788-8869
MAIL ADDRESS:
STREET 1: 1371 EAST 2100 SOUTH
STREET 2: SUITE 200
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84105
FORMER COMPANY:
FORMER CONFORMED NAME: EYEGATE PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20060811
4
1
tm2228925-3_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-10-21
0
0001372514
KIORA PHARMACEUTICALS INC
KPRX
0001892943
Daniels Eric Joseph
C/O KIORA PHARMACEUTICALS, INC
1371 E. 2100 SOUTH, SUITE 200
SALT LAKE CITY
UT
84105
0
1
0
0
Chief Development Officer
Common Stock
2022-10-21
4
A
0
10000
0
A
10238
D
Stock Option (right to buy)
6.78
2022-10-21
4
A
0
15000
0
A
2032-10-21
Common Stock
15000
15000
D
Grant of restricted stock from the Issuer pursuant to the Issuer's 2014 Equity Incentive Plan (the "Plan"). The restrictions will vest as to one-third (1/3) of the shares on each of October 21, 2023, October 21, 2024 and October 21, 2025, subject to the reporting person's continuous service through each such vesting date.
The reporting person received an option to purchase Common Stock from the Issuer pursuant to the Plan. The option will become exercisable as to one-third (1/3) of the shares underlying the Option on October 21, 2023, and the remaining balance vests monthly on the first day of each calendar month thereafter for a period of two years, subject to the reporting person's continuous service through each such vesting date.
/s/ Melissa Tosca, Attorney-in-Fact
2022-10-25